Previous 10 | Next 10 |
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than 5 years. This subset of the different portfolios I regularly analyze has now reached 120 weeks of public selections as part of this ongoing live forward-testing. In...
Company Thesis While there are over 50 million visits to U.S. hospitals for acute pain each year, AcelRx's ( ACRX ) new DSUVIA launch in Q12019 has only managed to capture $2.4 million in sales at its trailing two-quarter run-rate annualized. Current standards for acute pain management suc...
REDWOOD CITY, Calif. , Aug. 15, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Dr. Pamela Pal...
AcelRx Pharmaceuticals (NASDAQ: ACRX ): Q2 GAAP EPS of -$0.16 beats by $0.06 . More news on: AcelRx Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
REDWOOD CITY, Calif. , Aug. 5, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today reported its second q...
The attack on opioids is intensifying once again, and the circle of companies falling victim is widening. On Aug. 1, Reuters reported that the State of Oklahoma is now making its final efforts to hold Johnson & Johnson (JNJ) responsible. The Trump Administration has decided to restrict a...
REDWOOD CITY, Calif. , Aug. 2, 2019 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release second quarter financial results after market close on Monday, August 5th, 2019 . AcelRx management will host a l...
Overview of Products AcelRx has two products, Dsuvia and Zalviso. Dsuvia comes in the form of a sublingual tablet to be dissolved under the tongue, containing 30 micrograms of sufentanil. AcelRx has created a proprietary noninvasive delivery method through a one-time use, disposable applic...
AcelRx ( ACRX ) is newly arrived at the danger zone where it is attempting to market a newly FDA approved therapy for acute pain. I am dubious that it will succeed for the benefit of current shareholders on any near term time schedule. This article explains my thinking on the prospects and pit...
AcelRx ( ACRX ) is newly arrived at the danger zone where it is attempting to market a newly FDA approved therapy for acute pain. I am dubious that it will succeed for the benefit of current shareholders on any near term time schedule. This article explains my thinking on the prospects and pit...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...